Why the study?
Total blockade of RANKL/RANK causes unwanted effects beyond bone, and therapeutic peptide RM application was limited by instability and low cellular uptake.
Does RM-CCMV inhibit osteoclastogenesis and improve bone histomorphology in murine models of osteoporosis compared to free RM?
Does RM-CCMV inhibit osteoclastogenesis and improve bone histomorphology in murine models of osteoporosis compared to free RM?
Functionalizing the RANK-specific motif peptide onto virus nanoparticles significantly improves its cellular uptake and efficacy in inhibiting osteoclastogenesis, offering a promising targeted therapeutic strategy for osteoporosis.
May enable selective osteoporosis therapy in mice; leaves open human translation and clinical validation.
Osteoporosis is a common skeletal disease characterized by excessive osteoclast-induced bone loss. RANKL/RANK signaling pathway is essential for osteoclastogenesis and is a key target for osteoporosis. However, regarding the fact that RANKL/RANK also functions beyond bone, the total block of RANKL/RANK will have unwanted impact on other organs. Our previous study revealed that mutation of RANK-specific motifs inhibited osteoclastogenesis without effects on other organs in mice. However, the instability and low cellular uptake efficiency limited the application of the therapeutic peptide originating from the amino acid sequence of RANK-specific motifs (RM). To this end, in this study, the peptide RM (SRPVQEQGGA (C to N terminal)) was chemically modified onto the surface of the plant virus-based nanoparticles cowpea chlorotic mottle virus (CCMV). Subsequent experiments showed that the novel virus nanoparticles RM-CCMV had excellent biocompatibility and stability, which ultimately facilitated its cellular uptake efficiency and improved its inhibitive effects on osteoclastogenesis. Moreover, RM-CCMV achieved bone enrichment and suppressed bone resorption by inhibiting osteoclastogenesis and improving the parameters of bone histomorphology in murine femurs. To be mentioned, the effective dose of CCMV conjugated RM was only 6.25% of free RM. In summary, these results have provided a promising therapeutic strategy for osteoporosis.
No takes yet. Share an insight, caveat, or question.
Cao et al. (2023) studied Osteoporosis. RM-CCMV (peptide RM chemically modified onto cowpea chlorotic mottle virus nanoparticles) vs. free RM was evaluated on Osteoclastogenesis and bone histomorphology parameters.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: